Bausch Health Companies Inc.
In the published model solve dated 2026-Q2, anchored at $6.56, Bausch Health Companies Inc. (BHC) is priced for +10.5% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• Equity here is a thin residual: about 1.7 billion dollars of market value sits above roughly 19.5 billion of net borrowings, so a small move in the value of the whole enterprise swamps the share price in either direction. • The growth is coming from the asset with the shortest legal clock, with Salix segment profit up 26% to $468 million in the March 2026 quarter and the 10-Q stating that ⟦"Xifaxan was the primary contributor to growth for the three months ended March 31, 2026"⟧. • Second-quar
Is BHC overvalued? See what's priced in →
217 institutional managers reported holding BHC in 13F filings for the quarter ended 2026-03-31. Together they hold about 62% of the company; the top 10 hold 45%. 21 opened new positions that quarter. Held by Vanguard Group, KKR, Goldman Sachs, among others. On the short side, 7.4M shares were sold short as of the 2026-06-15 count, about 2% of shares outstanding (3.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BHC's share count grew 3.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BHC over the trailing three years: 2025: 9 buys totaling $385.25M. 17 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BHC's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -3.0% | -10.5% |
| 2023-11-03 | +6.7% | +8.5% |
| 2024-02-23 | +5.9% | -5.0% |
| 2024-05-03 | -10.6% | -7.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BHC's latest 8-K filings: 2026-07-29 (items 2.02, 9.01); 2026-07-01 (items 5.02, 7.01, 9.01); 2026-05-19 (items 5.07); 2026-04-29 (items 2.02, 9.01); 2026-03-02 (items 5.02).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.